Industry Call for Opportunities

In Situ Generation of Antimicrobial Compounds via Biological Processes

A global FSTE top 20 FMCG company with business in Hygiene is seeking research focused on in situ generation of biologically (microbe or enzyme) generated antimicrobials. Our client wishes to identify antimicrobial molecule generation, as well as biological molecule to antimicrobial molecule generation.

Approaches of Interest

**Microbe to antimicrobial agent generation.** Examples of this could include, but are not limited to:

- Probiotic generation of post-biotics: post-biotics could include antimicrobial peptides (AMPs), antimicrobial lipids (AMLs), organic acid species (e.g. lactic acid and citric acid...), and endospores
- Fungi to molecule generation: such as mycotoxins, enzymes, quorum-sensing molecules

**Biologic to antimicrobial agent generation.** For example:

- Enzymes such as glucose oxidase (H2O2 production in situ)
- Isolated enzymes that are produced by microbes but in their own right produce antimicrobial agents (such as AMPs and AMLs)
- Ideally, the agents may be associated with a positive impact/change to the environment on the skin and/or hard surface

Opportunities with the following are of highest interest:

- Where the agent produced is already registered as a biocidal active agent
- Safety testing has been conducted on biocatalysts and the agents generated
- Robust efficacy testing has conducted to show the antimicrobial properties of the opportunity
- There is a clear strategy or road map to understand registration of the technology with regulatory bodies
- Residue testing of technology to show long-lasting effect/colonisation effect of technology

Key Information

**Example Applications:** Hard surface cleaners, personal care rinse off and leave on skin products, wipes or other surface sanitisation formats, laundry formats.

**Out of Scope:** Non-biological catalysts and photocatalytic in situ generators.

**Stage of Development:** Our client is interested in basic research through to clinical phase 1 (TRL3+). Applications with validations e.g. *in vitro*, *ex vivo* and/or *in vivo* data is of the highest interest.

**Submission Information:** Submission of one-page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

**Potential Collaborations for Academics:** Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licencing, consulting, project funding and research collaborations.

Opportunities sought

- Spinout companies
- Research projects
- Centres of excellence
- Academics and expertise
- Technologies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: 6th December 2021 - 11:59 pm GMT

Have any questions? Contact our team at discover@in-part.co.uk